Concepedia

Author

Sandro Pignata

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"ORCID

Also Known As

A.M. Perrone, Anna Maria Mosconi, Bruno Daniele, Domenica Lorusso, Donatello Gasparro, Emanuele Naglieri, Federica Zito Marino, Ferdinando Riccardi, Francesco Pierantoni, Nicoletta Colombo

894

Publications

34.5K

Citations

80

H-Index

147

Concepts

All Affiliations

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Istituti di Ricovero e Cura a Carattere ScientificoFondazione IRCCS Istituto Nazionale dei TumoriAgostino Gemelli University PolyclinicEuropean Institute of Oncology
SP

About

Sandro Pignata is an author at Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" specializing in medicine, oncology, and obstetrics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

47

142

16.5K

2

Health Sciences

20

31

1.8K

3

Public Health

7

7

1.4K

4

Engineering

1

1

16

5

Natural Sciences

1

1

19

Sandro Pignata

×

273

Publications

25.2K

Citations

67

H-Index

YearCitations

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata,

New England Journal of Medicine

2019

1.9K

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle,

The Lancet Oncology

2017

1.8K

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso,

The Lancet

2017

1.7K

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

Nicoletta Colombo, Cristiana Sessa, Andreas du Bois,

Annals of Oncology

2019

1.1K

Radiofrequency Ablation of Unresectable Primary and Metastatic Hepatic Malignancies

Steven A. Curley, Francesco Izzo, Paolo Delrio,

Annals of Surgery

1999

1.1K

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

Ursula A. Matulonis, Ronnie Shapira‐Frommer, Alessandro D. Santin,

Annals of Oncology

2019

786

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse

Éric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist,

Journal of Clinical Oncology

2010

558

The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer

David Cibula, Richard Pötter, François Planchamp,

International Journal of Gynecological Cancer

2018

470

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann,

The Lancet Oncology

2021

391

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros,

The Lancet Oncology

2014

386

Page 1